{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:01:38Z","timestamp":1792551698824,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol Suppl"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11789-017-0085-0","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T09:28:17Z","timestamp":1486459697000},"page":"2-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["PCSK9 targets important for lipid metabolism"],"prefix":"10.1007","volume":"12","author":[{"given":"Rainer","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Dieter","family":"Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"85_CR1","doi-asserted-by":"publisher","first-page":"166ra1","DOI":"10.1126\/scitranslmed.3004853","volume":"5","author":"RH Al-Mashhadi","year":"2013","unstructured":"Al-Mashhadi RH, Sorensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, Thim T, Du Y, Li J, Liu Y, Moldt B, Schmidt M, Vajta G, Larsen T, Purup S, Bolund L, Nielsen LB, Callesen H, Falk E, Mikkelsen JG, Bentzon JF (2013) Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a\u00a0human PCSK9 gain-of-function mutant. Sci Transl Med 5:166ra1. doi: 10.1126\/scitranslmed.3004853","journal-title":"Sci Transl Med"},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","volume":"100","author":"KM Argraves","year":"1997","unstructured":"Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK (1997) The atherogenic lipoprotein Lp(a) is internalized and degraded in a\u00a0process mediated by the VLDL receptor. J\u00a0Clin Invest 100:2170\u20132181","journal-title":"J Clin Invest"},{"key":"85_CR3","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.m409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG (2004) NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J\u00a0Biol Chem 279:48865\u201344875. doi: 10.1074\/jbc.m409699200","journal-title":"J Biol Chem"},{"key":"85_CR4","doi-asserted-by":"publisher","first-page":"30561","DOI":"10.1074\/jbc.m606495200","volume":"281","author":"S Benjannet","year":"2006","unstructured":"Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281:30561\u201330572. doi: 10.1074\/jbc.m606495200","journal-title":"J. Biol. Chem."},{"issue":"17","key":"85_CR5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/circulationaha.115.016080","volume":"132","author":"N Bergeron","year":"2015","unstructured":"Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM (2015) Proprotein convertase subtilisin\/kexin type 9 inhibition: a\u00a0new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132(17):1648\u20131666. doi: 10.1161\/circulationaha.115.016080","journal-title":"Circulation"},{"issue":"11","key":"85_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/circresaha.114.302937","volume":"114","author":"MM Bjorklund","year":"2014","unstructured":"Bjorklund MM, Hollensen AK, Hagensen MK, Dagnaes-Hansen F, Christoffersen C, Mikkelsen JG, Bentzon JF (2014) Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res 114(11):1684\u20131689. doi: 10.1161\/circresaha.114.302937","journal-title":"Circ Res"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"G519","DOI":"10.1152\/ajpgi.00189.2007","volume":"293","author":"DD Black","year":"2007","unstructured":"Black DD (2007) Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion. Am J Physiol Gastrointest Liver Physiol 293:G519\u2013G524","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"85_CR8","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1038\/tp.2015.167","volume":"5","author":"HN Buttenschon","year":"2015","unstructured":"Buttenschon HN, Demontis D, Kaas M, Elfving B, Molgaard S, Gustafsen C, Kaerlev L, Petersen CM, B\u00f8rglum AD, Mors O, Glerup S (2015) Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF. Transl Psychiatry 5:e677. doi: 10.1038\/tp.2015.167","journal-title":"Transl Psychiatry"},{"key":"85_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.trsl.2012.01.010","volume":"160","author":"J Cameron","year":"2012","unstructured":"Cameron J, Bogsrud MP, Tveten K, Strom TB, Holven K, Berge KE, Leren TP (2012) Serum levels of proprotein convertase subtilisin\/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin\/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Transl Res 160:125\u2013130. doi: 10.1016\/j.trsl.2012.01.010","journal-title":"Transl Res"},{"key":"85_CR10","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG (2013) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLOS ONE 8:e64145. doi: 10.1371\/journal.pone.0064145","journal-title":"PLOS ONE"},{"key":"85_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1194\/jlr.m010603","volume":"52","author":"A Cao","year":"2011","unstructured":"Cao A, Wu M, Li H, Liu J (2011) Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J\u00a0Lipid Res 52:518\u2013530. doi: 10.1194\/jlr.m010603","journal-title":"J Lipid Res"},{"key":"85_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.atherosclerosis.2010.04.015","volume":"211","author":"B Cariou","year":"2010","unstructured":"Cariou B, Le Bras M, Langhi C, Le May C, Guyomarc\u2019h-Delasalle B, Krempf M, Costet P (2010) Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 211:700\u2013702. doi: 10.1016\/j.atherosclerosis.2010.04.015","journal-title":"Atherosclerosis"},{"key":"85_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/mol.0000000000000239","volume":"26","author":"MJ Chapman","year":"2015","unstructured":"Chapman MJ, Stock JK, Ginsberg NH (2015) PSCK9 inhibitors and cardiovascular disease: heralding a\u00a0new therapeutic era. Curr Opin Lipidol 26:511\u2013520. doi: 10.1097\/mol.0000000000000239","journal-title":"Curr Opin Lipidol"},{"key":"85_CR14","doi-asserted-by":"publisher","first-page":"e00444","DOI":"10.7554\/elife.00444","volume":"2","author":"XW Chen","year":"2013","unstructured":"Chen XW, Wang H, Bajaj K, Zhang P, Meng ZX, Ma D, Bai Y, Liu HH, Adams E, Baines A, Yu G, Sartor MA, Zhang B, Yi Z, Lin J, Young SG, Schekman R, Ginsburg D (2013) SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife 2:e00444. doi: 10.7554\/elife.00444","journal-title":"Elife"},{"key":"85_CR15","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.1074\/jbcM.508582200","volume":"281","author":"P Costet","year":"2006","unstructured":"Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M (2006) Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J\u00a0Biol Chem 281:6211\u20136218. doi: 10.1074\/jbcM.508582200","journal-title":"J Biol Chem"},{"key":"85_CR16","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1111\/jcmm.12931","volume":"20","author":"CJ Cui","year":"2016","unstructured":"Cui CJ, Li S, Zhu CG, Sun J, Du Y, Zhang Y, Wu NQ, Guo YL, Xu RX, Gao Y, Li JJ (2016) Enhanced pro-protein convertase subtilisin\/kexin type 9 expression by C\u2011reactive protein through p38MAPK-HNF1\u03b1 pathway in HepG2 cells. J\u00a0Cell Mol Med 20:2374\u20132383. doi: 10.1111\/jcmm.12931","journal-title":"J Cell Mol Med"},{"key":"85_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nsmb1235","volume":"14","author":"D Cunningham","year":"2007","unstructured":"Cunningham D, Danley DE, Geoghegan DF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Mansour MN, McGrath KM, Seddon AP, Shenolikar S, Stutzman-Engwall KJ, Warren LC, Xia D, Qiu X (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14:413\u2013419. doi: 10.1038\/nsmb1235","journal-title":"Nat Struct Mol Biol"},{"key":"85_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/atvbaha.115.306032","volume":"35","author":"A Demers","year":"2015","unstructured":"Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, Mayer G (2015) PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol 35:2517\u20132525. doi: 10.1161\/atvbaha.115.306032","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"85_CR19","doi-asserted-by":"publisher","first-page":"10805","DOI":"10.1074\/jbc.m113.001969","volume":"288","author":"RM DeVay","year":"2013","unstructured":"DeVay RM, Shelton DL, Liang H (2013) Characterization of proprotein convertase subtilisin\/kexin type 9 (PCSK9) trafficking reveals a\u00a0novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J\u00a0Biol Chem 288(15):10805\u201310818. doi: 10.1074\/jbc.m113.001969","journal-title":"J Biol Chem"},{"key":"85_CR20","doi-asserted-by":"publisher","first-page":"e0125127","DOI":"10.1371\/journal.pone.0125127","volume":"10","author":"RM DeVay","year":"2015","unstructured":"DeVay RM, Yamamoto L, Shelton DL, Liang H (2015) Common Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function. PLOS ONE 10:e0125127. doi: 10.1371\/journal.pone.0125127","journal-title":"PLOS ONE"},{"issue":"6","key":"85_CR21","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1194\/jlr.m003556","volume":"51","author":"B Dong","year":"2010","unstructured":"Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, Liu J (2010) Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance of LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J\u00a0Lipid Res 51(6):1486\u20131495. doi: 10.1194\/jlr.m003556","journal-title":"J Lipid Res"},{"key":"85_CR22","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.atv.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24:1454\u20131459. doi: 10.1161\/01.atv.0000134621.14315.43","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"85_CR23","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0022-2275(20)32043-5","volume":"41","author":"J Fan","year":"2010","unstructured":"Fan J, Challah M, Shimoyamada H, Shiomi M, Marcovina S, Watanabe T (2010) Defects of the LDL receptor in WHHL transgenic rabbits lead to a\u00a0marked accumulation of plasma lipoprotein[a]. J\u00a0Lipid Res 41(6):1004\u20131012","journal-title":"J Lipid Res"},{"key":"85_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","volume":"374","author":"KR Feingold","year":"2008","unstructured":"Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C (2008) Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 374:341\u2013344. doi: 10.1016\/j.bbrc.2008.07.023","journal-title":"Biochem Biophys Res Commun"},{"key":"85_CR25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12020-016-0939-0","volume":"54","author":"N Ferri","year":"2016","unstructured":"Ferri N, Ruscica M (2016) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 54:588\u2013601","journal-title":"Endocrine"},{"key":"85_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","volume":"220","author":"N Ferri","year":"2012","unstructured":"Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL (2012) Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 220:381\u2013386. doi: 10.1016\/j.atherosclerosis.2011.11.026","journal-title":"Atherosclerosis"},{"key":"85_CR27","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1074\/jbc.m701634200","volume":"282","author":"TS Fisher","year":"2007","unstructured":"Fisher TS, Lo SP, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De FR, Wright SD, Sparrow CP, Carfi A, Sitlani A (2007) Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J\u00a0Biol Chem 282:20502\u201320512. doi: 10.1074\/jbc.m701634200","journal-title":"J Biol Chem"},{"issue":"1","key":"85_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/nejmoa1609243","volume":"376","author":"K Fitzgerald","year":"2016","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A (2016) A highly durable RNAi therapeutic inhibitor of PCSK9. N\u00a0Eng J Med 376(1):41\u201351. doi: 10.1056\/nejmoa1609243","journal-title":"N Eng J Med"},{"issue":"33","key":"85_CR29","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1073\/pnas.0805434105","volume":"105","author":"M Frank-Kamenetsky","year":"2008","unstructured":"Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher H\u2011P, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105(33):11915\u201311920. doi: 10.1073\/pnas.0805434105","journal-title":"Proc Natl Acad Sci USA"},{"key":"85_CR30","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/oby.21656","volume":"24","author":"A Gagnon","year":"2016","unstructured":"Gagnon A, Ooi TC, Cousins M, Favreau C, Henry K, Landry A, Sorisky A (2016) The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants. Obesity (Silver Spring) 24:2384\u20132391. doi: 10.1002\/oby.21656","journal-title":"Obesity (Silver Spring)"},{"key":"85_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","volume":"119","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ (2017) Effect of alirocumab on lipoprotein(a) over \u22651.5 years (from the phase 3 ODYSSEY program). Am J Cardiol 119:40\u201346. doi: 10.1016\/j.amjcard.2016.09.010","journal-title":"Am J Cardiol"},{"key":"85_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.832","author":"JP Gibbs","year":"2016","unstructured":"Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, Xu RY, Johnson J, Wasserman SM, Emery MG (2016) Evaluation of evolocumab (AMG 145), a\u00a0fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment. J\u00a0Clin Pharmacol. doi: 10.1002\/jcph.832","journal-title":"J Clin Pharmacol"},{"key":"85_CR33","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1194\/jlr.m800027-jlr200","volume":"49","author":"A Grefhorst","year":"2008","unstructured":"Grefhorst A, McNutt MC, Lagace TA, Horton JD (2008) Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J\u00a0Lipid Res 49:1303\u20131311. doi: 10.1194\/jlr.m800027-jlr200","journal-title":"J Lipid Res"},{"key":"85_CR34","doi-asserted-by":"publisher","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","volume":"5","author":"N Gupta","year":"2010","unstructured":"Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLOS ONE 5:e10682. doi: 10.1371\/journal.pone.0010682","journal-title":"PLOS ONE"},{"key":"85_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cemt.2013.12.006","volume":"19","author":"C Gustafsen","year":"2014","unstructured":"Gustafsen C, Kjolby M, Nyegaard M, Mattheisen M, Lundhede J, Buttenschon H, Mors O, Bentzon JF, Madsen P, Nykjaer A, Glerup S (2014) The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab 19:310\u2013318. doi: 10.1016\/j.cemt.2013.12.006","journal-title":"Cell Metab"},{"key":"85_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB (2016) The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134:61\u201372. doi: 10.1161\/CIRCULATIONAHA.115.020912","journal-title":"Circulation"},{"key":"85_CR37","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.0703402104","volume":"104","author":"EN Hampton","year":"2007","unstructured":"Hampton EN, Knuth MW, Li J, Harris JL, Leslie SA, Spraggon G (2007) The self-inhibited structure of full-length PCSK9 at 1.9\u202fA reveals structural homology with resistin within the C\u2011terminal domain. Proc Natl Acad Sci USA 104:14604\u201314609. doi: 10.1073\/pnas.0703402104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"85_CR38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1194\/jlr.m049346","volume":"55","author":"B Han","year":"2014","unstructured":"Han B, Eacho PI, Knierman MD, Troutt JS, Konrad RJ, Yu X, Schroeder KM (2014) Isolation and characterization of the circulating truncated form of PCSK9. J\u00a0Lipid Res 55(7):1505\u20131514. doi: 10.1194\/jlr.m049346","journal-title":"J Lipid Res"},{"key":"85_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","volume":"62","author":"J Hoover-Plow","year":"2013","unstructured":"Hoover-Plow J, Huang M (2013) Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 62:479\u2013491. doi: 10.1016\/j.metabol.2012.07.024","journal-title":"Metabolism"},{"key":"85_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1194\/jlr.m700443-jlr200","volume":"49","author":"HJ Jeong","year":"2008","unstructured":"Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW (2008) Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol regulatory element-binding protein-2. J\u00a0Lipid Res 49:399\u2013409. doi: 10.1194\/jlr.m700443-jlr200","journal-title":"J Lipid Res"},{"issue":"2","key":"85_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2010.10.028","volume":"214","author":"PJ Kapelle","year":"2011","unstructured":"Kapelle PJ, Lambert G, Dullaart RP (2011) Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24\u202fh insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis 214(2):432\u2013435. doi: 10.1016\/j.atherosclerosis.2010.10.028","journal-title":"Atherosclerosis"},{"key":"85_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ddtec.2005.08.012","volume":"2","author":"S Kauppinen","year":"2005","unstructured":"Kauppinen S, Vester B, Wengel J (2005) Locked nucleic acid (LNA): high affinity targeting of RNA for diagnosis and therapeutics. Drug Discov Today Technol 2:287\u2013290. doi: 10.1016\/j.ddtec.2005.08.012","journal-title":"Drug Discov Today Technol"},{"key":"85_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11883-015-0496-7","volume":"17","author":"M Kjolby","year":"2015","unstructured":"Kjolby M, Nielsen MS, Petersen CM (2015) Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease. Curr Atheroscler Rep 17:496. doi: 10.1007\/s11883-015-0496-7","journal-title":"Curr Atheroscler Rep"},{"key":"85_CR44","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1074\/jbc.m112.421370","volume":"288","author":"T Kosenko","year":"2013","unstructured":"Kosenko T, Golder M, Leblond G, Weng W, Lagace TA (2013) Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J\u00a0Biol Chem 288:8279\u20138288. doi: 10.1074\/jbc.m112.421370","journal-title":"J Biol Chem"},{"key":"85_CR45","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1073\/pnas.0712064105","volume":"105","author":"HJ Kwon","year":"2008","unstructured":"Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 105:1820\u20131825. doi: 10.1073\/pnas.0712064105","journal-title":"Proc Natl Acad Sci USA"},{"key":"85_CR46","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","volume":"69","author":"K Kysenius","year":"2012","unstructured":"Kysenius K, Muggalla P, Matlik K, Arumae U, Huttunen HJ (2012) PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 69:1903\u20131916. doi: 10.1007\/s00018-012-0977-6","journal-title":"Cell Mol Life Sci"},{"key":"85_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hep.22911","volume":"50","author":"P Labonte","year":"2009","unstructured":"Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG (2009) PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 50:17\u201324. doi: 10.1002\/hep.22911","journal-title":"Hepatology"},{"key":"85_CR48","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J\u00a0Clin Endocrinol Metab 94:2537\u20132543. doi: 10.1210\/jc.2009-0141","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"85_CR49","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/atvbaha.108.181586","volume":"29","author":"C May Le","year":"2009","unstructured":"Le May C, Kourimate S, Langhi C, Ch\u00e9tiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P (2009) Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 29(5):684\u2013690. doi: 10.1161\/atvbaha.108.181586","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"85_CR50","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1210\/en.2015-1624","volume":"157","author":"AE Levenson","year":"2016","unstructured":"Levenson AE, Haas ME, Miao J, Brown RJ, de Ferranti SD, Muniyappa R, Biddinger SB (2016) Effect of leptin replacement on PCSK9 in ob\/ob mice and female lipodystrophic patients. Endocrinology 157:1421\u20131429. doi: 10.1210\/en.2015-1624","journal-title":"Endocrinology"},{"key":"85_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","volume":"227","author":"E Levy","year":"2013","unstructured":"Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier \u00c9, Emonnot L, Yara S, Couture P, Beaulieu JF, M\u00e9nard D, Seidah NG, Elchebly M (2013) PCSK9 plays a\u00a0significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 227:297\u2013306. doi: 10.1016\/j.atherosclerosis.2013.01.023","journal-title":"Atherosclerosis"},{"issue":"42","key":"85_CR52","doi-asserted-by":"publisher","first-page":"28885","DOI":"10.1074\/jbc.m109.052407","volume":"284","author":"H Li","year":"2009","unstructured":"Li H, Dong B, Park SW, Lee H\u2011S, Chen W, Liu J (2009) Hepatocyte nuclear factor 1alpha plays a\u00a0critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J\u00a0Biol Chem 284(42):28885\u201328895. doi: 10.1074\/jbc.m109.052407","journal-title":"J Biol Chem"},{"issue":"6","key":"85_CR53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jacbts.2016.08.007","volume":"1","author":"P Libby","year":"2016","unstructured":"Libby P (2016) Lipoprotein (a): a frustrating final frontier in lipid management? JACC Basic Transl Sci 1(6):428\u2013431. doi: 10.1016\/j.jacbts.2016.08.007","journal-title":"JACC Basic Transl Sci"},{"key":"85_CR54","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/mt.2011.260","volume":"20","author":"MW Lindholm","year":"2012","unstructured":"Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, Moller MR, Rosenbohm C, Orum H, Straarup EM, Koch T (2012) PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 20:376\u2013381. doi: 10.1038\/mt.2011.260","journal-title":"Mol. Ther."},{"key":"85_CR55","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1194\/jlr.m006635","volume":"51","author":"M Liu","year":"2010","unstructured":"Liu M, Wu G, Baysarowich J, Kavana M, Addona GH, Bierilo KK, Mudgett JS, Pavlovic G, Sitlani A, Renger JJ, Hubbard BK, Fisher TS, Zerbinatti CV (2010) PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J\u00a0Lipid Res 51:2611\u20132618. doi: 10.1194\/jlr.m006635","journal-title":"J Lipid Res"},{"key":"85_CR56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","volume":"12","author":"P Lo Surdo","year":"2011","unstructured":"Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carf\u00ed A (2011) Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH. EMBO Rep 12:1300\u20131305. doi: 10.1038\/embor.2011.205","journal-title":"EMBO Rep."},{"key":"85_CR57","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a\u00a0low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101:7100\u20137105. doi: 10.1073\/pnas.0402133101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"85_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/mol.0b013e32835e809c","volume":"24","author":"P May","year":"2013","unstructured":"May P (2013) The low-density lipoprotein receptor-related protein 1 in inflammation. Curr Opin Lipidol 24(2):134\u2013137. doi: 10.1097\/mol.0b013e32835e809c","journal-title":"Curr Opin Lipidol"},{"key":"85_CR59","doi-asserted-by":"publisher","first-page":"31791","DOI":"10.1074\/jbc.m805971200","volume":"283","author":"G Mayer","year":"2008","unstructured":"Mayer G, Poirier S, Seidah NG (2008) Annexin A2 is a\u00a0C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J\u00a0Biol Chem 283:31791\u201331801. doi: 10.1074\/jbc.m805971200","journal-title":"J Biol Chem"},{"key":"85_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511x-7-22","volume":"7","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chretien M (2008) Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 7:22. doi: 10.1186\/1476-511x-7-22","journal-title":"Lipids Health Dis"},{"key":"85_CR61","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jacc.2011.11.064","volume":"59","author":"M Melone","year":"2012","unstructured":"Melone M, Wilsie L, Palyha O, Strack A, Rashid S (2012) Discovery of a\u00a0new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin\/kexin type 9. J\u00a0Am Coll Cardiol 59:1697\u20131705. doi: 10.1016\/j.jacc.2011.11.064","journal-title":"J Am Coll Cardiol"},{"key":"85_CR62","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1161\/atvbaha.115.305688","volume":"35","author":"J Miao","year":"2015","unstructured":"Miao J, Manthena PV, Haas ME, Ling AV, Shin DJ, Graham MJ, Crooke RM, Liu J, Biddinger SB (2015) Role of insulin in the regulation of proprotein convertase subtilisin\/kexin type 9. Arterioscler Thromb Vasc Biol 35:1589\u20131596. doi: 10.1161\/atvbaha.115.305688","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"85_CR63","doi-asserted-by":"publisher","first-page":"12882","DOI":"10.1074\/jbc.m110.113035","volume":"285","author":"YG Ni","year":"2010","unstructured":"Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carf\u00ed A, Sitlani A (2010) A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C\u2011terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J\u00a0Biol Chem 285:12882\u201312891. doi: 10.1074\/jbc.m110.113035","journal-title":"J Biol Chem"},{"issue":"22","key":"85_CR64","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"S Nicholls","year":"2016","unstructured":"Nicholls S, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brenann DM, Nissen SE (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316(22):2373. doi: 10.1001\/jama.2016.16951","journal-title":"JAMA"},{"key":"85_CR65","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1507\/endocrj.ej15-0308","volume":"62","author":"C Ozkan","year":"2015","unstructured":"Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F (2015) Proprotein convertase subtilisin\/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer. Endocr\u00a0J 62:1091\u20131099. doi: 10.1507\/endocrj.ej15-0308","journal-title":"Endocr J"},{"key":"85_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25767","author":"F Paciullo","year":"2017","unstructured":"Paciullo F, Fallarino F, Bianconi V, Mannarino MR, Sahebkar A, Pirro M (2017) PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J\u00a0Cell Physiol 7. doi: 10.1002\/jcp.25767","journal-title":"J Cell Physiol"},{"key":"85_CR67","doi-asserted-by":"publisher","first-page":"50630","DOI":"10.1074\/jbc.m410077200","volume":"279","author":"SW Park","year":"2014","unstructured":"Park SW, Moon YA, Horton JD (2014) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver. J\u00a0Biol Chem 279:50630\u201350638. doi: 10.1074\/jbc.m410077200","journal-title":"J Biol Chem"},{"key":"85_CR68","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1194\/jlr.P071704","volume":"57","author":"M Peach","year":"2016","unstructured":"Peach M, Xu R, Fitzpatrick D, Hamilton L, Somaratne R, Scott R, Wasserman SM, Djedjos CS (2016) Effect of evolocumab on cholesterol synthesis and absorption. J\u00a0Lipid Res 57:2217\u20132224","journal-title":"J Lipid Res"},{"key":"85_CR69","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.m708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J\u00a0Biol Chem 283:2363\u20132372. doi: 10.1074\/jbc.m708098200","journal-title":"J Biol Chem"},{"key":"85_CR70","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.celrep.2015","volume":"13","author":"S Poirier","year":"2015","unstructured":"Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G (2015) GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Rep 13:2064\u20132071. doi: 10.1016\/j.celrep.2015","journal-title":"Cell Rep"},{"key":"85_CR71","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","volume":"102","author":"FJ Raal","year":"2005","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 102:5374\u20135379. doi: 10.1073\/pnas.0501652102","journal-title":"Proc Natl Acad Sci USA"},{"key":"85_CR72","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1194\/jlr.p065334","volume":"57","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role. J\u00a0Lipid Res 57:1086\u20131096. doi: 10.1194\/jlr.p065334","journal-title":"J Lipid Res"},{"key":"85_CR73","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","volume":"102","author":"S Rashid","year":"2005","unstructured":"Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 102:5374\u20135379. doi: 10.1073\/pnas.0501652102","journal-title":"Proc Natl Acad Sci USA"},{"key":"85_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/atvbaha.110.220988","volume":"31","author":"A Roubtsova","year":"2011","unstructured":"Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A (2011) Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31:785\u2013791. doi: 10.1161\/atvbaha.110.220988","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"85_CR75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","volume":"48","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P (2016) Liver fat accumulation is associated with circulating PCSK9. Ann Med 48:384\u2013391. doi: 10.1080\/07853890.2016.1188328","journal-title":"Ann Med"},{"key":"85_CR76","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1074\/jbc.m115.664706","volume":"291","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, Ferri N (2016) Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J\u00a0Biol Chem 291:3508\u20133519. doi: 10.1074\/jbc.m115.664706","journal-title":"J Biol Chem"},{"key":"85_CR77","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s2213-8587(16)00003-6","volume":"4","author":"N Sattar","year":"2016","unstructured":"Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a\u00a0meta-analysis of individual patient data. Lancet Diabetes Endocrinol 4:403\u2013140. doi: 10.1016\/s2213-8587(16)00003-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"85_CR78","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jmb.2013.11.011","volume":"426","author":"F Schiele","year":"2014","unstructured":"Schiele F, Park J, Redemann N, Luippold G, Nar H (2014) An antibody against the C\u2011terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J\u00a0Mol Biol 426:843\u2013852. doi: 10.1016\/j.jmb.2013.11.011","journal-title":"J Mol Biol"},{"key":"85_CR79","unstructured":"Schl\u00fcter K-D, Weber M, Schreckenberg R, Schulz R (2016) ox-LDL and Angiotensin: Cooperative effects via induction of PCSK9 in cardiomyocytes. Clin Res Cardiol 105, Suppl 1, V1278"},{"key":"85_CR80","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz R, Schl\u00fcter K\u2011D, Laufs U (2015) Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol 110:4. doi: 10.1007\/s00395-015-0463-z","journal-title":"Basic Res Cardiol"},{"key":"85_CR81","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1194\/jlr.p065334","volume":"57","author":"R Scott","year":"2016","unstructured":"Scott R, Stein EA (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role. J\u00a0Lipid Res 57:1086\u20131096. doi: 10.1194\/jlr.p065334","journal-title":"J Lipid Res"},{"key":"85_CR82","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","volume":"59","author":"A Sehgal","year":"2013","unstructured":"Sehgal A, Vaishnaw A, Fitzgerald K (2013) Liver as a\u00a0target for oligonucleotide therapeutics. J\u00a0Hepatol 59:1354\u20131359. doi: 10.1016\/j.jhep.2013.05.045","journal-title":"J Hepatol"},{"key":"85_CR83","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/circresaha.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chretien M, Mbikay M (2014) PCSK9: a\u00a0key modulator of cardiovascular health. Circ Res 114:1022\u20131036. doi: 10.1161\/circresaha.114.301621","journal-title":"Circ Res"},{"key":"85_CR84","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100:928\u2013933. doi: 10.1073\/pnas.0335507100","journal-title":"Proc Natl Acad Sci USA"},{"key":"85_CR85","doi-asserted-by":"publisher","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","volume":"7","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G (2012) Annexin A2 is a\u00a0natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLOS ONE 7:e41865. doi: 10.1371\/journal.pone.0041865","journal-title":"PLOS ONE"},{"key":"85_CR86","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11:367\u2013383. doi: 10.1038\/nrd3699","journal-title":"Nat Rev Drug Discov"},{"key":"85_CR87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","volume":"375","author":"L Shan","year":"2008","unstructured":"Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA (2008) PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 375:69\u201373. doi: 10.1016\/j.bbrc.2008.07.106","journal-title":"Biochem Biophys Res Commun"},{"key":"85_CR88","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/circresaha.115.306471","volume":"118","author":"MD Shapiro","year":"2016","unstructured":"Shapiro MD, Fazio S (2016) From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 118:732\u2013749. doi: 10.1161\/circresaha.115.306471","journal-title":"Circ Res"},{"key":"85_CR89","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.febslet.2013.02.027","volume":"587","author":"L Shen","year":"2013","unstructured":"Shen L, Peng HC, Nees SN, Zhao SP, Xu DY (2013) Proprotein convertase subtilisin\/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Lett 587:1271\u20131274. doi: 10.1016\/j.febslet.2013.02.027","journal-title":"FEBS Lett"},{"key":"85_CR90","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1194\/jlr.m052969","volume":"56","author":"VR Shende","year":"2015","unstructured":"Shende VR, Wu M, Singh AB, Dong B, Can CF, Liu J (2015) Reduction of PCSK9 and LDL-C levels by liver-specific knockdown of HNF1alpha in normolipemic mice. J\u00a0Lipid Res 56:801\u2013809. doi: 10.1194\/jlr.m052969","journal-title":"J Lipid Res"},{"key":"85_CR91","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"ES Stroes","year":"2014","unstructured":"Stroes ES, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M (2014) Anti-PCSK-9 antibody effectively lowers cholesterol in patients with statin intolerance. J\u00a0Am Coll Cardiol 63:2541\u20132548. doi: 10.1016\/j.jacc.2014.03.019","journal-title":"J Am Coll Cardiol"},{"key":"85_CR92","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2016.02.027","volume":"248","author":"E Sucajtys-Szulc","year":"2016","unstructured":"Sucajtys-Szulc E, Szolkiewicz M, Swierczynski J, Rutkowski B (2016) Up-regulation of Hnf1\u03b1 gene expression in the liver of rats with experimentally induced chronic renal failure \u2013 a possible link between circulating PCSK9 and triacylglycerol concentrations. Atherosclerosis 248:17\u201326. doi: 10.1016\/j.atherosclerosis.2016.02.027","journal-title":"Atherosclerosis"},{"key":"85_CR93","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11010-015-2590-0","volume":"411","author":"E Sucajtys-Szulc","year":"2016","unstructured":"Sucajtys-Szulc E, Szolkiewicz M, Swierczynski J, Rutkowski B (2016) Up-regulation of liver Pcsk9 gene expression as a\u00a0possible cause of hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem 411:281\u2013287. doi: 10.1007\/s11010-015-2590-0","journal-title":"Mol Cell Biochem"},{"key":"85_CR94","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/circulationaha.113.0011592","volume":"127","author":"H Tavori","year":"2013","unstructured":"Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S (2013) Serum protease converatse subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a\u00a0reciprocal regulation. Circulation 127:2403\u20132413. doi: 10.1161\/circulationaha.113.0011592","journal-title":"Circulation"},{"key":"85_CR95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/circresaha.116.308811","volume":"119","author":"H Tavori","year":"2016","unstructured":"Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S (2016) PCSK9 association with lipoprotein(a). Circ Res 119:29\u201335. doi: 10.1161\/circresaha.116.308811","journal-title":"Circ Res"},{"key":"85_CR96","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/circulationaha.113.001592","volume":"127","author":"H Tavori","year":"2013","unstructured":"Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S (2013) Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a\u00a0reciprocal regulation. Circulation 127:2403\u20132413. doi: 10.1161\/circulationaha.113.001592","journal-title":"Circulation"},{"key":"85_CR97","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","volume":"15","author":"PP Toth","year":"2016","unstructured":"Toth PP, Hamon SC, Jones SR, Martin SS, Joshi PH, Kulkarni KR, Banerjee P, Hanotin C, Roth EM, McKenney JM (2016) Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis 15:28. doi: 10.1186\/s12944-016-0197-4","journal-title":"Lipids Health Dis"},{"key":"85_CR98","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/bcp.12738","volume":"80","author":"EP Poelgeest Van","year":"2015","unstructured":"Van Poelgeest EP, Hodges MR, Moerland M, Tesiier Y, Levin AA, Persson R, Lindholm MW, Dumong Erichsen K, Orum H, Cohen AF, Burggraaf J (2015) Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a\u00a0first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol 80:1350\u20131361. doi: 10.1111\/bcp.12738","journal-title":"Br J Clin Pharmacol"},{"key":"85_CR99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/atvbaha.116.307995","volume":"37","author":"R Verbeek","year":"2017","unstructured":"Verbeek R, Boyer M, Boekholdt SM, Hovingh GK, Kastelein JJ, Wareham N, Khaw KT, Arsenault BJ (2017) Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy-brief report. Arterioscler Thromb Vasc Biol 37:43\u201348. doi: 10.1161\/atvbaha.116.307995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"85_CR100","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","volume":"1","author":"EF Villard","year":"2016","unstructured":"Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TTT, Poirier B, Le Bail JC, Illiano S, Nob\u00e9court E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G (2016) PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab. JACC Basic Transl Sci 1(6):419\u2013427. doi: 10.1016\/j.jacbts.2016.06.006","journal-title":"JACC Basic Transl Sci"},{"key":"85_CR101","doi-asserted-by":"publisher","first-page":"25843","DOI":"10.1126\/scitranslmed.3008782","volume":"6","author":"KR Walley","year":"2014","unstructured":"Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH (2014) PCSK9 is a\u00a0critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 6:25843. doi: 10.1126\/scitranslmed.3008782","journal-title":"Sci Transl Med"},{"key":"85_CR102","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.febslet.2015.01.007","volume":"589","author":"X Wang","year":"2015","unstructured":"Wang X, Berry E, Hernandez-Anzaldo S, Sun D, Adijiang A, Li L, Zhang D, Fernandez-Patron C (2015) MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells. FEBS Lett 589:490\u2013496. doi: 10.1016\/j.febslet.2015.01.007","journal-title":"FEBS Lett"},{"key":"85_CR103","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1194\/jlr.m028563","volume":"53","author":"Y Wang","year":"2012","unstructured":"Wang Y, Huang Y, Hobbs HH, Cohen JC (2012) Molecular characterization of proprotein convertase subtilisin\/kexin type 9\u2011mediated degradation of the LDLR. J\u00a0Lipid Res 53:1932\u20131943. doi: 10.1194\/jlr.m028563","journal-title":"J Lipid Res"},{"key":"85_CR104","doi-asserted-by":"publisher","first-page":"12086","DOI":"10.3390\/molecules171012086","volume":"17","author":"W Xu","year":"2012","unstructured":"Xu W, Liu L, Hornby D (2012) c\u2011IAP1 binds and processes PCSK9 protein: linking the c\u2011IAP1 in a\u00a0TNF-alpha pathway to PCSK9-mediated LDLR degradation pathway. Molecules 17:12086\u201312101. doi: 10.3390\/molecules171012086","journal-title":"Molecules"},{"key":"85_CR105","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1073\/pnas.0806312105","volume":"105","author":"DW Zhang","year":"2008","unstructured":"Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 105:13045\u201313050. doi: 10.1073\/pnas.0806312105","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Clinical Research in Cardiology Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11789-017-0085-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T17:49:52Z","timestamp":1658598592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11789-017-0085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":105,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s11789-017-0085-0","relation":{},"ISSN":["1861-0706","1861-0714"],"issn-type":[{"value":"1861-0706","type":"print"},{"value":"1861-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}